OmniAb Investor Presentation Deck
Performance Indicators
SIGNIFICANT GROWTH IN ACTIVE PARTNERS AND ACTIVE PROGRAMS
●
4 new license agreements signed in Q2
New platform license agreements with Merck & Co.
Inc., Neurocrine Biosciences Inc., Stanford University,
and Seattle Children's Hospital
●
Strong annual growth in key performance
indicators continues, net of attrition
- Active Partners:(1)~18% CAGR 2016 through 2022
Active Programs:(2) ~25% CAGR 2016 through 2022
• Metrics position our business for growth
80
70
60
50
40
30
20
10
Number of Active
Partners
2016
2017
2018
2019
2020
2021
2022
6/30/2023
350
300
250
200
150
100
50
(1) Represents the unique number of partners that have an active program or have executed a license agreement in advance of initiating an active program.
(2) Represents programs for which research work has commenced or an antigen is introduced into our animals and remains so as long as the program is actively
being developed or commercialized.
Number of Active
Programs
2016
2017
2018
2019
2020
2021
2022
6/30/2023
7
OmniAbView entire presentation